Actively Recruiting
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2025-03-20
54
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
CONDITIONS
Official Title
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to sign informed consent before starting screening
- Male or female aged 12 years or older
You will not qualify if you...
- Major surgery within 4 weeks before first dose or expected during the trial (except vascular access or biopsy)
- Unresolved treatment-related adverse reactions worse than grade 1
- Treatment with strong CYP3A inhibitor or inducer within 7 days before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
X
xiaojuan Lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here